Antitope's senior management team comprises individuals with successful track records from a broad cross section of the biotechnology and pharmaceutical industry.
Matthew Baker Ph.D
Chief Executive Officer & Chief Scientific Officer,
Formerly VP for Biologics Discovery at Biovation Ltd, a subsidiary of Merck KGaA. Matthew led an experienced team at Biovation/Merck which successfully developed novel biologics for inflammation, blood disorders, infection and cancer.
Frank Carr Ph.D
Director for Biologics Research,
Formerly Chief Executive Officer at Biovation Ltd and was the inventor of the DeImmunisation™ technology. Previously he co-invented "germ-lining" humanization technology at Scotgen Biopharmaceuticals which is now established as a standard technology for humanization.
William Dawson Ph.D
Formerly Director of Research for Eli Lilly UK and previously a director at Biovation Ltd. Bill is a member of the board of Proteome Sciences plc, Creative Peptides Ltd and Onyvax Ltd, and he is also Managing Director of Bionet Ltd.
Tim Jones Ph.D
Formerly a Senior Research Manager at Biovation Ltd where he was responsible for the development of several deimmunised therapeutic antibodies and proteins.
Neil Butt Ph.D
Business Development Director,
Formerly a manager with PA Consulting Group with particular responsibility for projects with biopharmaceutical companies and for business development in the pharmaceutical industry.